生物活性 | |||
---|---|---|---|
描述 | Lirafugratinib (RLY-4008) hydrochloride is an orally active, irreversible, and highly selective FGFR2 inhibitor with an IC50 of 3 nM. It covalently binds to Cys491 and targets FGFR2 primary alterations and resistance mutations, inducing tumor regression while sparing other FGFRs[1]. |
实验方案 | |||
---|---|---|---|
1mg | 5mg | 10mg | |
1 mM 5 mM 10 mM |
1.83mL 0.37mL 0.18mL |
9.16mL 1.83mL 0.92mL |
18.32mL 3.66mL 1.83mL |
参考文献 |
---|